The natural history of hepatitis C virus (HCV) infection

International Journal of Medical Sciences

Volumn 3, Issue 2, 2006, Pages 47-52

  Chen, Stephen L ^a,b   Morgan, Timothy R ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute; Chronic; Cirrhosis; HCC; HCV; Hepatitis C; Hepatocellular carcinoma; Liver fibrosis; Natural history

Indexed keywords

ACUTE DISEASE; ALCOHOL CONSUMPTION; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CLINICAL FEATURE; COMORBIDITY; DEMOGRAPHY; DISEASE COURSE; DISEASE TRANSMISSION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORBIDITY; PREVALENCE; REVIEW;

EID: 33646250428     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.3.47     Document Type: Review

References (70)

1. Wasley A and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis, 2000. 20(1): 1-16.
2. Alter M.J. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis, 1997. 1(3): 559-68.
3. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant, 2001. 1(3): 197-203.
4. [No authors listed]. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology, 2002. 123(6): 2082-99.
5. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep, 1998. 47: 1-39.
6. Choo Q.L, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989. 244(4902): 359-62.
7. Lauer G.M and Walker B.D. Hepatitis C virus infection. N Engl J Med, 2001. 345(1): 41-52.
8. Neumann AU, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 1998. 282(5386): 103-7.
9. Bukh J, Miller R.H., and Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis, 1995. 15(1): 41-63.
10. Dodd R.Y, Notari E.P.t., and Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 2002. 42(8): 975-9.
11. Roth W.K, et al. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion, 2002. 42(7): 862-8.
12. Schreiber G.B, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med, 1996. 334(26): 1685-90.
13. Alter M.J, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med, 1999. 341(8): 556-62.
14. McCaughan G.W, et al. Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors. Med J Aust, 1992. 157(4): 231-3.
15. Alter H.J and Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis, 2000. 20(1): 17-35.
16. Thimme R, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med, 2001. 194(10): 1395-406.
17. Farci P, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med, 1991. 325(2): 98-104.
18. Farci P, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med, 1996. 335(9): 631-4.
19. Vogt M, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med, 1999. 341(12): 866-70.
20. Sasaki N, et al. Loss of circulating hepatitis C virus in children who developed a persistent carrier state after mother-to-baby transmission. Pediatr Res, 1997. 42(3): 263-7.
21. Bellentani S and Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol, 2001. 35(4): 531-7.
22. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med, 1999. 340(16): 1228-33.
23. Wiese M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology, 2000. 32(1): 91-6.
24. Seeff L.B, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology, 2001. 33(2): 455-63.
25. Villano S.A, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology, 1999. 29(3): 908-14.
26. Howell C, Jeffers L., and Hoofnagle J.H. Hepatitis C in African Americans: summary of a workshop. Gastroenterology, 2000. 119(5): 1385-96.
27. Nguyen M.H, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol, 2004. 2(9): 820-4.
28. Gruner N.H, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis, 2000. 181(5): 1528-36.
29. Lechner F, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med, 2000. 191(9): 1499-512.
30. Thomas D.L, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama, 2000. 284(4): 450-6.
31. Wiley T.E, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology, 1998. 28(3): 805-9.
32. Noda K, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma - its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res, 1996. 20(1 Suppl): 95A-100A.
33. Ostapowicz G, et al. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology, 1998. 27(6): 1730-5.
34. Peters M.G and Terrault N.A. Alcohol use and hepatitis C. Hepatology, 2002. 36(5 Suppl 1): S220-5.
35. Pessione F, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology, 1998. 27(6): 1717-22.
36. Corrao G and Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology, 1998. 27(4): 914-9.
37. Harris D.R, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med, 2001. 134(2): 120-4.
38. Poynard T, Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 1997. 349(9055): 825-32.
39. Ryder S.D, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut, 2004. 53(3): 451-5.
40. Yano M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology, 1996. 23(6): 1334-40.
41. Ragni M.V and Belle S.H. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis, 2001. 183(7): 1112-5.
42. Benhamou Y, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology, 1999. 30(4): 1054-8.
43. Di Martino V, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology, 2001. 34(6): 1193-9.
44. Lesens O, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis, 1999. 179(5): 1254-8.
45. Bjoro K, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med, 1994. 331(24): 1607-11.
46. Berenguer M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol, 2000. 32(4): 673-84.
47. D'Souza R, Sabin C.A., and Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol, 2005. 100(7): 1509-15.
48. Fartoux L, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut, 2005. 54(7): 1003-8.
49. Romero-Gomez M, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 2005. 128(3): 636-41.
50. Muzzi A, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol, 2005. 42(1): 41-6.
51. Fattovich G, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology, 1997. 112(2): 463-72.
52. Serfaty L, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 1998. 27(5): 1435-40.
53. Hu K.Q and Tong M.J. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology, 1999. 29(4): 1311-6.
54. Donato F, Boffetta P., and Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer, 1998. 75(3): 347-54.
55. Ikeda K, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology, 1999. 29(4): 1124-30.
56. Fattovich G, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology, 1995. 21(1): 77-82.
57. Nishiguchi S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 1995. 346(8982): 1051-5.
58. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet, 1998. 351(9115): 1535-9.
59. Papatheodoridis G.V, Papadimitropoulos V.C., and Hadziyannis S.J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther, 2001. 15(5): 689-98.
60. Tong M.J, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med, 1995. 332(22): 1463-6.
61. Seeff L.B. Natural history of chronic hepatitis C. Hepatology, 2002. 36(5 Suppl 1): S35-46.
62. Castells L, et al. Long interval between HCV infection and development of hepatocellular carcinoma. Liver, 1995. 15(3): 159-63.
63. Gordon S.C, Bayati N., and Silverman A.L. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology, 1998. 28(2): 562-7.
64. Degos F, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut, 2000. 47(1): 131-6.
65. Chiba T, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol, 1996. 31(4): 552-8.
66. Bruno S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology, 1997. 25(3): 754-8.
67. Gumber S.C and Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med, 1995. 123(8): 615-20.
68. El-Serag H.B, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology, 2002. 36(6): 1439-45.
69. Cacoub P, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore), 2000. 79(1): 47-56.
70. Lunel F and Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol, 1999. 31 (Suppl 1): 210-6.